SEARCH

SEARCH BY CITATION

References

  • 1
    Van den Burg PJH, Hospers JEH, Van Vliet M, Mosterd WL, Bouma BN, Huisveld IA. Changes in haemostatic factors and activation products after exercise in healthy subjects with different ages. Thromb Haemost 1995; 74: 145764.
  • 2
    DeSouza CA, Jones PP, Seals DR. Physical activity status and adverse age-related differences in coagulation and fibrinolytic factors in women. Arterioscler Thromb Vasc Biol 1998; 18: 3628.
  • 3
    Naesh O, Hindberg I, Trap-Jensen J, Lund JO. Post-exercise platelet activation-aggregation and release in relation to dynamic exercise. Clin Physiol 1990; 10: 22130.
  • 4
    Andrew M, Carter C, O'Brodovich H, Heigenhauser G. Increases in factor VIII complex and fibrinolytic activity are dependent on exercise intensity. J Appl Physiol 1986; 60: 191722.
  • 5
    Weiss C, Seitel G, Bärtsch P. Coagulation and fibrinolysis after moderate and very heavy exercise in healthy male subjects. Med Sci Sports Exerc 1998; 30: 24651.
  • 6
    Rosing DR, Brakman P, Redwood DR, Goldstein RE, Beiser GD, Astrup T, Epstein SE. Blood fibrinolytic activity in man. Diurnal variation and the response to varying intensities of exercise. Circ Res 1970; 27: 17184.
  • 7
    Brozovic M. Physiological mechanisms in coagulation and fibrinolysis. Br Med Bull 1977; 33: 2318.
  • 8
    Jern C, Eriksson E, Tengborn L, Risberg B, Wadenvik H, Jern S. Changes of plasma coagulation and fibrinolysis in response to mental stress. Thromb Haemost 1989; 62: 76771.
  • 9
    Jern C, Manhem K, Eriksson E, Tengborn L, Risberg B, Jern S. Hemostatic responses to mental stress during the menstrual cycle. Thromb Haemost 1991; 66: 6148.
  • 10
    Snieder H, Huizink AC, Boomsma DY, Van Doornen LJP. Influence of mental stress on fibrinogen, von Willebrand factor and tissue-type plasminogen activator antigen. Fibrinolysis 1996; 10 (Suppl. 2): 1379.
  • 11
    Palmblad J, Blombäck M, Egberg N, Fröberg J, Karlsson CG, Levi L. Experimentally induced stress in man: effects on blood coagulation and fibrinolysis. J Psychosom Res 1977; 21: 8792.
  • 12
    Bremme K, Östlund E, Almqvist I, Heinonen K, Blombäck M. Enhanced thrombin generation and fibrinolytic activity in normal pregnancy and the puerperium. Obstet. Gynecol 1992; 80: 1327.
  • 13
    Kjellberg U, Andersson NE, Rosen S, Tengborn L, Hellgren M. APC resistance and other haemostatic variables during pregnancy and puerperium. Thromb Haemost 1999; 81: 52731.
  • 14
    Bremme KA. Haemostatic changes in pregnancy. Best Pract Res Clin Haematol 2003; 16: 15368.
  • 15
    Clark P, Brennand J, Conkie JA, McCall F, Greer IA, Walker ID. Activated protein C sensitivity, protein C, protein S and coagulation in normal pregnancy. Thromb Haemost 1998; 79: 116670.
  • 16
    Blombäck M, Eneroth P, Landgren BM, Lagerström M, Anderson O. On the intraindividual and gender variability of haemostatic components. Thromb Haemost 1992; 67: 705.
  • 17
    Siegbahn A, Odlind V, Hedner U, Venge P. Coagulation and fibrinolysis during the menstrual cycle. Ups J Med Sci 1989; 94: 13752.
  • 18
    Wramsby ML, Bokarewa MI, Blombäck M, Bremme AK. Response to activated protein C during normal menstrual cycle and ovarian stimulation. Hum Reprod 2000; 15: 7957.
  • 19
    Carr ME Jr, Steingold KA, Zekert SL. Protein S during the normal menstrual cycle and during estrogen therapy for premature ovarian failure. Am J Med Sci 1993; 306: 2127.
  • 20
    Kapiotis S, Jilma B, Pernerstorfer T, Stohlawetz P, Eichler HG, Speiser W. Plasma levels of activated factor VII decrease during the menstrual cycle. Thromb Haemost 1998; 80: 58891.
  • 21
    Jacobs HG, Selle G. The question of bleeding tendency after dental surgery during menstruation. Dtsch Zahnarztl Z 1974; 29: 10747.
  • 22
    Kadir RA, Economides DL, Sabin CA, Owens D, Lee CA. Variations in coagulation factors in women: effects of age, ethnicity, menstrual cycle and combined oral contraceptive. 1999; 82: 145661.
  • 23
    Miller CH, Dilley AB, Drews C, Richardson L, Evatt B. Changes in von Willebrand factor and factor VIII levels during the menstrual cycle. Thromb Haemost 2002; 87: 10823.
  • 24
    Feuring M, Christ M, Roell A, Schueller P, Losel R, Dempfle CE, Schultz A, Wehling M. Alterations in platelet function during the ovarian cycle. Blood Coagul Fibrinolysis 2002; 13: 4437.
  • 25
    Onundarson PT, Gudmundsdottir BR, Amfinnsdottir AV, Kjeld M, Olafsson O. Von Willebrand factor does not vary during the menstrual cycle. Thromb Haemost 2001; 85: 1834.
  • 26
    Lindberg UB, Crona N, Stigendal L, Teger-Nilsson AC, Silfverstolpe G. A comparison between effects of estradiol valerate and low dose ethinyl estradiol on haemostasis parameters. Thromb Haemost 1989; 61: 659.
  • 27
    Kemmeren JM, Algra A, Meijers JC, Bouma BN, Grobbee DE. Effects of second and third generation oral contraceptives and their respective progestagens on the coagulation system in the absence or presence of the factor V Leiden mutation. Thromb Haemost 2002; 87: 199205.
  • 28
    Meade TW, Haines AP, Imeson JD, Stirling Y, Thompson SG. Menopausal status and haemostatic variables. Lancet 1983; 1: 2224.
  • 29
    Caine YG, Bauer KA, Barzegar S, Ten Cate H, Sacks FM, Walsh BW, Schift I, Rosenberg RD. Coagulation activation following estrogen administration to postmenopausal women. Thromb Haemost 1992; 68: 3925.
  • 30
    Luyer MD, Khosla S, Owen WG, Miller VM. Prospective randomized study of effects of unopposed estrogen replacement therapy on markers of coagulation and inflammation in postmenopausal women. J Clin Endocrinol Metab 2001; 86: 362934.
  • 31
    Scarabin PY, Alhenc-Gelas M, Plu-Bureau G, Taisne P, Agher R, Aiach M. Effects of oral and transdermal estrogen/progesterone regimens on blood coagulation and fibrinolysis in postmenopausal women. A randomized controlled trial. Arterioscler Thromb Vasc Biol 1997; 17: 30718.
  • 32
    Oger E, Alhenc-Gelas M, Lacut K, Blouch MT, Roudaut N, Coller M, Abgrall JF, Aiach M, Scarabin PY, Mottier D, SARAH Investigators. Differential effects of oral and transdermal estrogen/progesterone regimens on sensitivity to activated protein C among postmenopausal women: a randomized trial. Arterioscler Thromb Vasc Biol 2003; 23: 16716.
  • 33
    Dalby MC, Davidson SJ, Burman JF, Davies SW. Diurnal variation in platelet aggregation with PFA-100 platelet function analyser. Platelets 2000; 11: 3204.
  • 34
    Haus E, Cusulos M, Sackett-Lundeen L, Swoyer J. Circadian variations in blood coagulation parameters, alpha-antitrypsin antigen and platelet aggregation and retention in clinically healthy subjects. Chronobiol Int 1990; 7: 20316.
  • 35
    Kapiotis S, Jilma B, Quehenberger P, Ruzicka K, Handler S, Speiser W. Morning hypercoagulability and hypofibrinolysis. Diurnal variations in circulating activated factor VII, prothrombin fragment F1+2, and plasmin-plasmin inhibitor complex. Circulation 1997; 96: 1921.
  • 36
    Undar L, Ertugrul C, Altunbas H, Akca S. Circadian variations in natural coagulation inhibitors protein C, protein S and antithrombin in healthy men: a possible association with interleukin-6. Thromb Haemost 1999; 81: 5715.
  • 37
    Fearnly G, Balmforth G, Fearnley E. Evidence of a diurnal fibrinolytic rhythm; with a simple method of measuring natural fibrinolysis. Clin Sci 1957; 16: 64550.
  • 38
    Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int 1991; 8: 33651.
  • 39
    Guder WG, Narayanan S, Wisser H, Zawta B. Samples: From the patient to the laboratory. 2nd ed. 2001: GIT Verlag GMBH: 18.